✦ LIBER ✦

Doxorubicin plus tumor necrosis factor α combination treatments in EL4-lymphoma-bearing C57BL/6 mice

✍ Scribed by M. J. Ehrke; Srdan Verstovšek; Peter Ujházy; Jane M. Meer; Cheryl Eppolito; Darbie L. Maccubbin; Enrico Mihich

Book ID: 105968267
Publisher: Springer-Verlag
Year: 1998
Tongue: English
Weight: 515 KB
Volume: 45
Category: Article
ISSN: 0340-7004
DOI: 10.1007/s002620050445

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Protective specific immunity induced by

Protective specific immunity induced by cyclophosphamide plus tumor necrosis factor α combination treatment of EL4-lymphoma-bearing C57BL/6 mice

✍ Christian M. Krawczyk; Srdan Verstovšek; Peter Ujházy; Darbie Maccubbin; M. Jane 📂 Article 📅 1997 🏛 Springer-Verlag 🌐 English ⚖ 92 KB

Protective specific immunity induced by

Protective specific immunity induced by doxorubicin plus TNF-α combination treatment of EL4 lymphoma–bearing C57BL/6 mice

✍ M. Jane Ehrke; Srdan Verstovšek; Darbie L. Maccubbin; Peter Ujházy; Gintaras Zal 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 French ⚖ 177 KB 👁 1 views

Tumor necrosis factor-α augmented tumor

Tumor necrosis factor-α augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil®) correlates with altered Doxil® pharmacokinetics

✍ Peter Brouckaert; Nozomi Takahashi; Sandra T. van Tiel; Jeroen Hostens; Alexande 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 332 KB

## Abstract The application of tumor necrosis factor‐α (TNF) for the treatment of solid tumors is limited by its severe, life‐threatening, toxicity. Therefore, only low dosages of this cytokine can be applied systemically, which results in poor tumor response. It has been demonstrated previously th